Tiziana Life Sciences (STU:0RP) Short Interest


STU:0RP Tiziana Life Sciences Ltd STU:0RP
28 GF Score
Price €1.09
! 2 Warning Signs
View Full Analysis

What is Tiziana Life Sciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:0RP vs SPRB, MIST, TNYA: Short Interest Comparison

For the Biotechnology subindustry, Tiziana Life Sciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tiziana Life Sciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Tiziana Life Sciences's Short Interest falls into.


STU:0RP
28GF Score
Tiziana Life Sciences Ltd STU:0RP
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tiziana Life Sciences Business Description

Other Exchanges TLSA:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM 11
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
28GF Score

Get the complete analysis for STU:0RP

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.09
Price